A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of DRL-17822 in Patients With Type II Hyperlipidemia.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of DRL-17822 in Patients With Type II Hyperlipidemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2014

At a glance

  • Drugs DRL 17822 (Primary)
  • Indications Hyperlipoproteinaemia type II
  • Focus Therapeutic Use
  • Sponsors Dr Reddys Laboratories
  • Most Recent Events

    • 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Mar 2012 Planned number of patients changed from 168 to 365 as reported by European Clinical Trials Database.
    • 29 Mar 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2011-001023-21).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top